TG 4010

Drug Profile

TG 4010

Alternative Names: Cancer vaccine - Transgene; MVA-MUC1-IL2; TG-4010; TG4010 MUC-1 targeted immunotherapy; VV-MUC-IL2

Latest Information Update: 02 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Transgene
  • Developer Transgene; University of California, Davis
  • Class Cancer vaccines; Membrane glycoproteins
  • Mechanism of Action Interleukin 12 stimulants; Mucin 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • Suspended Prostate cancer; Renal cell carcinoma
  • Discontinued Breast cancer

Most Recent Events

  • 25 Apr 2017 Transgene in collaboration with Bristol-Myers Squibb plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Combination therapy, First-line therapy)
  • 25 Apr 2017 Transgene and Bristol-Myers Squibb enter into a clinical research collaboration agreement to evaluate TG 4010 in combination with nivolumab and standard chemotherapy for Non-small cell lung cancer
  • 04 Jan 2017 Transgene terminates phase IIb/III trial in Non-small cell lung cancer in USA, Israel, Belgium, France, Germany, Hungary, Italy, Poland, Spain and the United Kingdom due to undisclosed reasons (NCT01383148)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top